Innogen Pharmaceutical Sets 29 June 2026 AGM; Seeks to Scrap Supervisory Committee and Launch Share Award Scheme

Bulletin Express06-05

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (“Innogen Pharmaceutical”), stock name INNOGEN-B, has issued a proxy circular outlining 24 resolutions to be tabled at its annual general meeting scheduled for 29 June 2026 in Shanghai.

Key ordinary resolutions • 2025 results package: shareholders will vote on the Board Report, Supervisory Committee Report, audited consolidated financial statements and the full annual report for the year ended 31 December 2025, together with a profit-distribution plan (details not disclosed in the circular). • Auditor: Ernst & Young is nominated for re-appointment as financial-report auditor for 2026, with the Board authorised to set remuneration. • Board composition: nine directors—four executive, two non-executive and three independent non-executive—are up for re-election, with remuneration to be confirmed at the meeting.

Key special resolutions • Governance restructure: the Board is proposing the complete abolition of the supervisory committee and corresponding amendments to the Articles of Association, alongside updates to the company’s business scope and changes to promoter names. • Procedural updates: revised Rules of Procedures for both the General Meeting and the Board of Directors will be submitted for approval. • Capital authorisations: – Share repurchase mandate covering up to 10% of total H shares in issue (excluding treasury shares). – Issuance mandate allowing the Board to allot and deal with H shares up to 20% of the current H-share base (excluding treasury shares). • Equity incentives: adoption of a Share Award Scheme, with an associated authorisation for the Board to handle implementation matters. The scheme includes a dedicated sub-limit of 4.57 million shares—approximately 1% of total issued shares—for service providers.

Logistics Proxy forms must reach Tricor Investor Services Limited (for H-shareholders) or the company’s designated address in Shanghai (for unlisted shareholders) by 10:00 a.m. on 28 June 2026, one day before the 10:00 a.m. AGM start time.

All resolutions will be determined by shareholder vote at the meeting or any adjournment thereof.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment